387 PUBLICATION Potential health economic benefits of adjuvant (A) trastuzumab (H) therapy of node-positive (N+) her-2+breast cancer (BC)

首页> 外文期刊>European Journal of Cancer Supplements >387 PUBLICATION Potential health economic benefits of adjuvant (A) trastuzumab (H) therapy of node-positive (N+) her-2+breast cancer (BC)

【24h】

387 PUBLICATION Potential health economic benefits of adjuvant (A) trastuzumab (H) therapy of node-positive (N+) her-2+breast cancer (BC)

机译：387出版物淋巴结阳性（N +）her-2 +乳腺癌（BC）的辅助治疗（A）曲妥珠单抗（H）治疗的潜在健康经济利益

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) to that of AC followed by paclitaxel plus trastuzumab (TH) in patients (pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC) [J] . C.Geyer, J.Bryant, E.Romond, European Journal of Cancer Supplements . 2004,第3期

机译：NSABP B-31第一阶段的心脏安全性分析，这是一项随机试验，比较了阿霉素和环磷酰胺（AC），紫杉醇（T）与AC，紫杉醇加曲妥珠单抗（TH）在患者中的安全性和有效性（pts ）可手术，淋巴结阳性（N +），HER-2过表达的乳腺癌（HER2 + BC）
2. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) [J] . Harbeck Nadia, Gluz Oleg, Christgen Matthias, Journal of Clinical Oncology . 2017,第26期

机译：人表皮生长因子受体2（HER2） - 阳性早期乳腺癌（BC）的脱升升级策略：对西德语研究组的最终分析辅助动态标记调整的个性化治疗试验优化BC HER2早期风险评估和治疗反应预测 - 激素受体阳性期II II型随机试验 - 疗效，安全性和预测标记为12周的Neoadjuvant Trastuzumab Omtansine，或没有内分泌治疗（ET）
3. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer [J] . RomondE.H., JeongJ.-H., RastogiP., Journal of Clinical Oncology . 2012,第31期

机译：NSABP B-31心功能的七年随访评估，一项随机试验，比较了阿霉素和环磷酰胺再加上紫杉醇（ACP）和ACP加曲妥珠单抗作为淋巴结阳性，人表皮生长因子受体2患者的辅助治疗阳性乳腺癌
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Determination of the potential use of beta-glucan as an adjuvant for monoclonal antibody immunotherapy of cancer. [D] . Hong, Feng. 2002

机译：确定β-葡聚糖作为癌症单克隆抗体免疫疗法佐剂的潜在用途。
6. Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31 a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer [O] . Edward H. Romond, Jong-Hyeon Jeong, Priya Rastogi, -1

机译：NSABP B-31多柔比星和环磷酰胺与紫杉醇（ACP）联合ACP加曲妥珠单抗作为辅助治疗淋巴结阳性人类表皮生长因子受体2的患者的随机试验的七年随访评估阳性乳腺癌
7. Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel [O] . Richard Robinson, Lorenzo Marconi, Ekelechi MacPepple, 2018

机译：节点阳性阴茎癌腹股沟淋巴结切除术后佐剂放射疗法的风险和益处：欧洲泌尿外科癌症指南面板系统审查

387 PUBLICATION Potential health economic benefits of adjuvant (A) trastuzumab (H) therapy of node-positive (N+) her-2+breast cancer (BC)

著录项

引文网络

相似文献

相关主题

期刊订阅